These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 31675535)

  • 1. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
    Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
    Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
    Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
    Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.
    Heist RS; Fain J; Chinnasami B; Khan W; Molina JR; Sequist LV; Temel JS; Fidias P; Brainerd V; Leopold L; Lynch TJ
    J Thorac Oncol; 2010 Oct; 5(10):1637-43. PubMed ID: 20808253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
    Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
    Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial.
    Kurata T; Kashii T; Takeda K; Seki N; Tsuboi M; Kobayashi M; Satoh T; Nakagawa K; Fukuoka M
    J Thorac Oncol; 2009 May; 4(5):644-8. PubMed ID: 19325498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.
    Cheng S; Evans WK; Stys-Norman D; Shepherd FA;
    J Thorac Oncol; 2007 Apr; 2(4):348-54. PubMed ID: 17409809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
    Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
    Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
    Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
    Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
    Paik PK; Rudin CM; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R; Markus S; Tyson L; Subzwari S; Kris MG; Krug LM
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1079-85. PubMed ID: 20165849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies.
    Johnson ML; Patel MR; Aljumaily R; Jones SF; Burris Iii HA; Spigel DR
    Oncologist; 2023 Jul; 28(7):640-e559. PubMed ID: 37129455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer.
    Beldner MA; Sherman CA; Green MR; Garrett-Mayer E; Chaudhary U; Meyer ML; Kraft AS; Montero AJ
    BMC Cancer; 2007 Dec; 7():231. PubMed ID: 18096059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis.
    Imai H; Yamada Y; Minemura H; Sugiyama T; Kotake M; Kaira K; Kanazawa K; Nakamura Y; Kasai T; Shibata Y; Kaburagi T; Minato K;
    Thorac Cancer; 2018 Dec; 9(12):1699-1706. PubMed ID: 30281216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.
    Jalal SI; Hanna N; Zon R; Masters GA; Borghaei H; Koneru K; Badve S; Prasad N; Somaiah N; Wu J; Yu Z; Einhorn L
    Am J Clin Oncol; 2017 Aug; 40(4):329-335. PubMed ID: 25503432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.
    Chiappori AA; Otterson GA; Dowlati A; Traynor AM; Horn L; Owonikoko TK; Ross HJ; Hann CL; Abu Hejleh T; Nieva J; Zhao X; Schell M; Sullivan DM
    Oncologist; 2016 Oct; 21(10):1163-1164. PubMed ID: 27694157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
    Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C;
    Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
    Kakolyris S; Kouroussis C; Souglakos J; Mavroudis D; Agelaki S; Kalbakis K; Androulakis N; Vardakis N; Vamvakas L; Georgoulias V
    Oncology; 2001; 61(4):265-70. PubMed ID: 11721172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.